Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCT-007 + PD-L1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Global Cancer Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
GCT-007 + PD-L1 inhibitor is a preclinical-stage combination therapy developed by Global Cancer Technology. The regimen combines GCT-007 (also known as GCT.GLIO.1), a selective, brain-penetrant small molecule inhibitor of Phosphoinositide 3-kinase (PI3K), with an undisclosed PD-L1 checkpoint inhibitor. This combination is designed to enhance anticancer activity by modulating immune cell function and converting immunologically cold tumors into hot tumors, thereby improving immune recognition and infiltration. Preclinical studies in glioblastoma models have demonstrated significant tumor elimination and superiority over other PI3K inhibitors like paxalisib. The therapy is currently being investigated for the treatment of glioblastoma (GBM), diffuse midline glioma (DIPG), and tamoxifen-resistant breast cancer.
- Other names
- GCT-007 (combination with PDL1/checkpoint inhibitor)GCT.GLIO.1 + PD-L1 inhibitor
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on GCT-007 + PD-L1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCT-007 + PD-L1 inhibitor.